Related Posts Plugin for WordPress, Blogger...


This week we went live with our newest analytic, RxSignal. For more information about our methodology, take a look at this brief video.

In short, RxSignal makes drug safety information predictable through a statistical signaling model that provides preemptive alerts to potential FDA communications and actions.

We have identified 28 drugs that have an “active” RxSignal, meaning that we believe these 28 drugs are likely to lead to FDA action. The following 5 drugs are on the list.

  • Jakafi
  • Adcirca
  • Xtandi
  • Arcalyst
  • Lastacaft

Using our RxOutcome analytic, we have found that costs from adverse events, and negative outcomes, rise by 349% from when an RxSignal alert is issued and the FDA takes action. If we can change prescribing behavior during this period we can significantly flatten the cost curve and improve patient safety.

If you want to know more about the why behind our RxSignal alerts on these drugs, or have any other questions, please contact us! 

 

Freedom of Information Act Request - FAERS Report download

 



Jim Davis

Jim Davis

Executive Vice President

Jim Davis LinkedinJim Davis Twitter

 

Topics: FDA, Drug / Indication Information, Evidex

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.